phrykt

Opus Genetics, Inc. (IRD): who owns it and who trades it

As of Nov 16, 2026, IRD insiders reported 24 open-market sales worth $19.7M and 2 purchases worth $324K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Foundation Fighting Blindness Retinal Degeneration Fund (Director), with $18.8M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Opus Genetics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IRD

103 funds and institutions reported IRD shares worth $250M at the end of Q2 2026, about 85% of the company. The largest holder is Nantahala Capital Management, LLC with 8.6%.

Funds and institutions (13F) 85%Everyone else 15%

10 largest owners, by share of the company

Nantahala Capital Management, LLC8.6%
Caligan Partners LP8.5%
Adage Capital Partners Gp, L.l.c.8.5%
BIOS Capital Management, LP5.2%
BlackRock, Inc.4.4%
Balyasny Asset Management L.P.4.3%
Vanguard Capital Management LLC4.2%
Boxer Capital Management, LLC4.0%
Trails Edge Capital Partners, LP3.9%
Millennium Management LLC3.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nantahala Capital Management, LLC6.12M8.61%$25.2M+264%
Caligan Partners LP6.08M8.54%$25MNo change
Adage Capital Partners Gp, L.l.c.6.03M8.47%$24.8MNo change
BIOS Capital Management, LP3.68M5.18%$15.1MNo change
BlackRock, Inc.3.12M4.38%$12.8M+2009%
Balyasny Asset Management L.P.3.09M4.34%$12.7M+14%
Vanguard Capital Management LLC2.96M4.16%$12.2M+21%
Boxer Capital Management, LLC2.81M3.96%$11.6M+25%
Trails Edge Capital Partners, LP2.74M3.86%$11.3M+449%
Millennium Management LLC2.30M3.24%$9.5M-12%
Great Point Partners LLC1.97M2.77%$8.1M+507%
Marshall Wace, LLP1.95M2.73%$8M-16%
ADAR1 Capital Management, LLC1.78M2.51%$7.3M-4%
Goldman Sachs Group Inc1.53M2.15%$6.3M+367%
Woodline Partners LP1.43M2.02%$5.9M+6%
Geode Capital Management, LLC1.37M1.92%$5.6M+154%
Boothbay Fund Management, LLC1.19M1.67%$4.9MNo change
Opaleye Management Inc.1.12M1.58%$4.6M+0%
SummitTX Capital, L.P.1.01M1.42%$4.1MNew
State Street Corp790,1361.11%$3.2M+295%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IRD insiders reported $324K of open-market purchases and $19.7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$324K
2 trades, 1 people
Sales, 12 months
$19.7M
24 trades, 7 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 3, 2026
Filed Nov 5, 2026

Purchases and sales by month

$8.6M$8.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 3, 2026George MagrathCEOSale28,258$3.90$110KForm 4
Oct 23, 2026Robert E. GagnonCFOSale plan14,000$3.55$49.6KForm 4
Oct 23, 2026George MagrathCEOSale9,591$3.58$34.4KForm 4
Oct 23, 2026Benjamin R YerxaPresidentSale7,669$3.55$27.2KForm 4
Oct 23, 2026Benjamin R YerxaPresidentSale25,520$3.53$90.1KForm 4
Oct 23, 2026Joseph K SchachleChief Operating OfficerSale4,767$3.56$17KForm 4
Sep 30, 2026Foundation Fighting Blindness Retinal Degeneration Fund +1DirectorSale556,000$4.96$2.8MForm 4
Sep 3, 2026Robert E. GagnonCFOSale28,000$4.54$127KForm 4
Jul 23, 2026Benjamin R YerxaPresidentSale7,429$2.97$22.1KForm 4
Jul 23, 2026Joseph K SchachleChief Operating OfficerSale4,644$2.94$13.7KForm 4
Jul 23, 2026George MagrathCEOSale9,475$2.95$28KForm 4
Jul 23, 2026Robert E. GagnonCFOSale7,783$2.95$23KForm 4
May 18, 2026Foundation Fighting Blindness Retinal Degeneration Fund +1DirectorSale1.70M$4.35$7.4MForm 4
Apr 23, 2026Benjamin R YerxaPresidentSale7,470$5.24$39.1KForm 4
Apr 23, 2026Joseph K SchachleChief Operating OfficerSale4,697$5.22$24.5KForm 4
Apr 23, 2026Rabourn Amy ZarembaHead of Fin. Quality AssSale1,641$5.20$8.5KForm 4
Apr 23, 2026George MagrathCEOSale9,511$5.22$49.6KForm 4
Apr 23, 2026Ashwath JayagopalChief Scientific & Dev. Sale7,542$5.19$39.1KForm 4
Apr 23, 2026Robert E. GagnonCFOSale7,842$5.18$40.6KForm 4
Mar 16, 2026Joseph K SchachleChief Operating OfficerSale3,719$5.25$19.5KForm 4
Mar 16, 2026Rabourn Amy ZarembaHead of Fin. Quality AssSale2,816$5.25$14.8KForm 4
Mar 16, 2026George MagrathCEOSale24,438$5.21$127KForm 4
Mar 16, 2026Ashwath JayagopalChief Scientific & Dev. Sale3,719$5.12$19KForm 4
Dec 29, 2025Cam GallagherDirectorPurchase81,000$1.98$160KForm 4
Dec 29, 2025Cam GallagherDirectorPurchase83,000$1.97$164KForm 4
Dec 9, 2025Foundation Fighting Blindness Retinal Degeneration Fund +1DirectorSale4.00M$2.15$8.6MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Foundation Fighting Blindness Retinal Degeneration FundDirector–$18.8MSep 30, 2026
George MagrathChief Executive Officer, Director–$349KNov 3, 2026
Cam GallagherDirector$324K–Dec 29, 2025
Robert E. GagnonChief Financial Officer–$240KOct 23, 2026
Benjamin R YerxaPresident, Director–$179KOct 23, 2026
Joseph K SchachleChief Operating Officer–$74.7KOct 23, 2026
Ashwath JayagopalChief Scientific & Dev. Ofc.–$58.2KApr 23, 2026
Rabourn Amy ZarembaHead of Fin. Quality Assurance–$23.3KApr 23, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IRD short interest

High short interest. 13.1% of IRD shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 249%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 10.86M IRD shares were sold short, 13.1% of the shares outstanding, down 18.5% from the report before. At the average daily volume of 1.30M shares, buying them all back would take about 8.4 trading days (days to cover).

Shares short, % of all shares

13.1%May 15Oct 3017.8%

Days to cover

8.4May 15Oct 3017.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.86M13.06%-19%1.30M8.4
Oct 15, 202613.34M16.03%+2%1.80M7.4
Sep 30, 202613.01M15.64%+3%2.15M6.0
Sep 15, 202612.58M15.12%+15%8.35M1.5
Aug 31, 202610.91M13.12%-3%878,18612.4
Aug 14, 202611.25M13.52%+4%733,90315.3
Jul 31, 202610.85M15.25%+6%908,93111.9
Jul 15, 202610.27M14.43%+25%820,06312.5
Jun 30, 20268.23M11.56%+43%1.57M5.2
Jun 15, 20265.74M8.06%+46%806,4347.1
May 29, 20263.92M5.51%+26%807,5814.8
May 15, 20263.11M4.37%+55%971,5853.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Opus Genetics company events

Opus Genetics filed 18 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 21, 2026LeadershipOpus Genetics, Inc. and Ashwath Jayagopal have agreed that Dr. Jayagopal will transition from his role as the Company’s Chief Scientific and Development Officer, effective as of October 19, 2026. Filing
  3. Oct 15, 2026AnnouncementShared information with investors. Filing
  4. Sep 11, 2026AnnouncementShared information with investors. Filing
  5. Sep 9, 2026AnnouncementThe Company shared 3- and 6-month results from the low-dose Cohort 1 of BIRD-1, the Company’s ongoing Phase 1/2 clinical trial of OPGx-BEST1 in patients with BEST1-related retinal diseases, including BVMD and ARB. Cohort 1 enrolled five participants treated at 1.5 x 10⁹ vg/eye: three participants… Filing
  6. Aug 6, 2026ResultsReleased financial results. Filing
  7. Jun 16, 2026AnnouncementShared information with investors. Filing
  8. Jun 16, 2026AnnouncementShared information with investors. Filing
  9. May 12, 2026ResultsReleased financial results. Filing
  10. Apr 24, 2026DebtTook on new debt. Filing
  11. Apr 22, 2026VoteReported shareholder vote results. Filing
  12. Apr 7, 2026LeadershipOpus Genetics, Inc. entered into a Change in Control Bonus Payment Agreement with each of Dr. George Magrath, Robert Gagnon, Joseph Schachle, and Dr. Ashwath Jayagopal, its Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and Chief Scientific and Development Officer… Filing
  13. Apr 7, 2026AgreementOpus Genetics, Inc., a Delaware corporation, and certain of its subsidiaries as guarantors, entered into a senior secured note purchase agreement with OPCM SA LLC, as purchaser agent, and certain purchasers party thereto. Filing
  14. Mar 10, 2026ResultsReleased financial results. Filing
  15. Feb 19, 2026AgreementOpus Genetics, Inc. entered into a securities purchase agreement with certain purchasers for a private placement of an aggregate of 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share. Filing
  16. Jan 12, 2026AnnouncementShared information with investors. Filing
  17. Jan 8, 2026AnnouncementShared information with investors. Filing
  18. Dec 19, 2025AnnouncementViatris Inc., the Company’s global commercialization partner for Phentolamine Ophthalmic Solution 0.75% (Phentolamine), filed a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA), for the treatment of presbyopia with Phentolamine. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Opus Genetics financials

Famous investors that hold IRD

2 of the 50 well-known investors we track reported holding IRD in their latest 13F filing. The largest position is Israel Englander's, worth $15.2M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20263.14M$15.2M0.0%+36%
Ken Griffin · Citadel AdvisorsQ3 2026497,481$2.4M0.0%-25%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 14 filings named IRD in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Boxer Capital Management, LLC13G5.4%
Nov 16, 2026Cormorant Asset Management, LP13G6.6%
Nov 16, 2026Cormorant Asset Management, LP13G6.6%
Nov 16, 2026Boxer Capital Management, LLC13G5.4%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A7.4%
Nov 16, 2026Caligan Partners LP13G/A6.2%
Nov 16, 2026BALYASNY ASSET MANAGEMENT L.P.13G/A7.4%
Nov 16, 2026Perceptive Advisors LLC13G/A10.0%
Nov 16, 2026Caligan Partners LP13G/A6.2%
Nov 16, 2026Perceptive Advisors LLC13G/A10.0%
Nov 12, 2026Adage Capital Management, L.P.13G/A2.7%
Nov 12, 2026Adage Capital Management, L.P.13G/A2.7%
Oct 27, 2026BlackRock, Inc.13G6.1%
Oct 27, 2026BlackRock, Inc.13G6.1%

Questions about Opus Genetics, Inc. (IRD) stock

Who owns the most IRD stock?

The largest reported owner of Opus Genetics, Inc. (IRD) is Nantahala Capital Management, LLC, with 8.6% of the company. In total, 103 funds and institutions reported holding IRD at the end of Q2 2026, together about 85% of the shares. See the largest owners.

Are IRD insiders buying or selling?

In the last 12 months, IRD insiders reported 2 open-market purchases worth $324K and 24 sales worth $19.7M. The latest trade was on Nov 3, 2026. See every trade.

What is the short interest in IRD?

As of Oct 30, 2026, 10.86M IRD shares were sold short, 13.1% of the shares outstanding, down 18.5% from the report before. At the average daily volume of 1.30M shares, buying them all back would take about 8.4 trading days (days to cover). See the history.

Which famous investors hold IRD?

2 of the 50 well-known investors we track reported IRD in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $15.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.